Cleveland Clinic Performs World’s First DBS Surgery for Stroke Recovery

Patient doing well, stimulation to start in coming weeks


Cleveland Clinic has performed the first deep brain stimulation (DBS) surgery in a patient for the purpose of restoring motor function following ischemic stroke.


Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

During a six-hour procedure on Dec. 19, 2016, a team led by Andre Machado, MD, PhD, implanted DBS electrodes in the cerebellum of the patient, who has severe post-stroke residual hemiparesis despite previous physical therapy. The patient has been discharged home feeling well and in stable condition.

Over the next few weeks, following adequate healing and recovery from the brain surgery, the patient will undergo physical therapy. After a few weeks of rehabilitation, the DBS device connected to the implanted electrodes will be turned on as the patient continues physical therapy. The patient will be monitored and evaluated regularly to determine whether and how DBS can enhance the effects of physical therapy.

The first-in-human operation is the initial case in an NIH-supported Cleveland Clinic trial of DBS for stroke recovery detailed previously on Consult QD.

“If this research succeeds, it is a new hope for patients who have remained paralyzed after a stroke,” says Dr. Machado, Chairman of Cleveland Clinic’s Neurological Institute and a neurosurgeon specializing in neuromodulation. “It is an opportunity to allow our patients to rehabilitate and gain function and independence. Our knowledge to date shows that deep brain stimulation can help the brain reorganize and adapt beyond what physical therapy alone can do. Our study’s goal is to boost rehabilitation outcomes beyond what physical therapy alone could achieve.”

More details about this initial case in the trial are available in a new Time magazine feature. Dr. Machado (shown in the foreground of the above photo) discusses the trial’s rationale and goals in this short Consult QD video.


Related Articles

Neurotrauma Guidelines: Where They’ve Been, Where They’re Headed and How to Make the Most of Them

Q&A with Brain Trauma Foundation guideline architect Gregory Hawryluk, MD, PhD

20-NEU-2020111 neuroimmunology_650x450
Autoimmune Neurologic Disorders: Treatable Conditions That Should Not Be Missed

Q&A with newly arrived autoimmune neurology specialist Amy Kunchok, MD

20-NEU-1984276 multimodal-monitoring_650x450
Multimodal Monitoring in the Neuro ICU: Essentials for Clinicians (Podcast)

A neurocritical care specialist shares what’s spurring growth of this new evaluation approach

central vein sign in multiple sclerosis
New Frontiers in Diagnosing and Monitoring Multiple Sclerosis (Podcast)

Get ready for central vein sign and optical coherence tomography

CGRP Antagonists for Decreasing Migraine Frequency: A Primer

How these new drugs fit into practice two years out from their first approvals

20-NEU-1892171 CQD_650x450_CCC-1901608_06-03-20_0443
What’s Afoot and What’s Ahead for Physical Medicine and Rehabilitation

A conversation on the state of physiatry with the AAPM&R’s Vice President